The National Medical Products Administration’s green light for Satri-cel, also known as CT041 or Kaileimei, signals a shift in oncology. For years, the scientific community has struggled to translate the success of CAR-T treatments from blood cancers to solid tumors. This breakthrough marks a transition point in medical research, with Jiahui International Cancer Center in Shanghai now preparing to integrate the therapy into its existing multidisciplinary oncology program.
China Approves World’s First CAR-T Therapy for Solid Tumors
A landmark regulatory approval in China has cleared the way for Satri-cel, the first CAR-T cell therapy designed to combat solid tumors. The treatment targets Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma, providing a vital option for patients who have exhausted at least two previous lines of standard therapy.
Dr. Linli Xuan, Chief of Medical Oncology at the center, described the approval as a milestone that solidifies China’s role in developing transformative cancer treatments. As international interest in these innovations grows, the facility is positioning itself as a primary access point for both domestic and global patients. The center utilizes a streamlined pathway involving precision medicine, surgical oncology, and specialized cellular therapy support to manage patients who travel from abroad for advanced care.
Comments (0)
No comments yet. Be the first!